Research

Researchers discuss a bile duct cancer project Bile duct cancer researchers

Doctors and scientists work together to develop new options for people with bile duct cancer.

Researchers at Mayo Clinic are studying new ways to diagnose and treat cholangiocarcinoma. This research is conducted as part of the Gastrointestinal Cancer Program and in coordination with the Mayo Clinic Cancer Center.

The Mayo Clinic Cancer Center receives funding from the National Cancer Institute (NCI) and is an NCI-designated comprehensive cancer center — recognition for an institution's scientific excellence and multidisciplinary resources focused on cancer prevention, diagnosis and treatment.

Areas of research include:

  • Discovering that aspirin use may help prevent bile duct cancer
  • Studying the molecular genetics of a tumor and identifying biomarkers, which may aid in early diagnosis or lead to new targeted therapies
  • Doing clinical trials for new targeted therapies, which is possible because of Mayo Clinic's high patient volume for primary sclerosing cholangitis and bile duct cancer
  • Improving safety of procedures and developing new ones
  • Proving that a biomarker called CA 19-9 is useful in staging a tumor

Publications

See a list of publications on cholangiocarcinoma by Mayo Clinic doctors on PubMed, a service of the National Library of Medicine.

Research Profiles

April 25, 2017
References
  1. AskMayoExpert. Cholangiocarcinoma. Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2016.
  2. Feldman M, et al. Tumors of the bile ducts, gallbladder and ampulla. In: Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. 10th ed. Philadelphia, Pa.: Saunders Elsevier; 2016. http://www.clinicalkey.com. Accessed Feb. 22, 2016.
  3. Rizvi S, et al. Current diagnostic and management options in perihilar cholangiocarcinoma. Digestion. 2014;89:216.
  4. Zaydfudim VM, et al. Hilar cholangiocarcinoma. Surgical Oncology Clinics of North America. 2014;23:247.
  5. Riggin EA. Allscipts EPSi. Mayo Clinic, Rochester, Minn. Oct. 27, 2016.
  6. Brown AY. Allscripts EPSi. Mayo Clinic, Rochester, Minn. Nov. 3, 2016.
  7. Smoot RL (expert opinion). Mayo Clinic, Rochester, Minn. March 23, 2017.
  8. Choi J, et al. Aspirin use and the risk of cholangiocarcinoma. Hepatology. 2016;64:785.
  9. Doherty B, et al. Update on the diagnosis and treatment of cholangiocarcinoma. Current Gastroenterology Reports. 2017;19:2.
  10. Borad MJ, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PloS Genetics 2014;10:e1004135. http://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1004135. Accessed Feb. 27, 2017.
  11. Barbara Woodward Lips Patient Education Center. Surgery on the extrahepatic bile duct, duodenum, papilla, or pancreas. Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2012.
  12. Merck Manual Professional Version. Tumors of the gallbladder and bile ducts. https://www.merckmanuals.com/professional/hepatic-and-biliary-disorders/gallbladder-and-bile-duct-disorders/tumors-of-the-gallbladder-and-bile-ducts#v902250. Accessed Feb. 28, 2017.
  13. Bergquist JR, et al. Implications of CA19-9 elevation for survival, staging and treatment sequencing in intrahepatic cholangiocarcinoma: A national cohort analysis. Journal of Surgical Oncology. 2016;114:475.